Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an αvβ3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on track for mid-2023; expected to be in clinic …